Home Science Serum Institute of India To Resume Oxford Vaccine Trials; Bharat Biotech's COVAXIN...

Serum Institute of India To Resume Oxford Vaccine Trials; Bharat Biotech’s COVAXIN Produces ‘Robust Immune Response’ In Animals

The Serum Institute of India finally got an approval to resume the vaccine trials of Covishield. Bharath Biotech's COVAXIN produced positive results in its trials on macaques.

Pune-based Serum Institute of India (SII) got an approval from the Drugs Controller General of India (DCGI) to resume the trials of the Oxford-AstraZeneca COVID-19 vaccine.

A few days ago, Oxford University put a temporary halt on the vaccine trials due to a suspected case of adverse reaction in one of the participants of the clinical trials. However, on 12th September, according to a report released by AstraZeneca, the Medicines Health Regulatory Authority (MHRA) permitted the resumption of the vaccine trials stating that it was ‘safe to do so’.

WireX August Download

Following this, SII also received approval to resume the trial of the vaccine known as Covishield in India. Adar Poonawalla, CEO of SII, tweeted:

As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford.

Despite the delay, AstraZeneca stated the vaccine is expected to be available by the end of the year or by early next year. Notably, these delays are a fairly common phenomenon in vaccine trials. Health Minister of UK, Matt Hancock, stated:

It’s a standard process in clinical trials. There was a pause earlier in the summer, and that was resolved without a problem.

Vaccine Candidate COVAXIN Produces Robust Immune Response In Monkeys

Recently, Bharat Biotech published the results of COVAXIN’s animal trials. The results indicated a decline in the viral replication in the nasal cavity, throat and lung tissues of monkeys. 

In the trials, 20 rhesus macaques (equally split into four groups) were given the vaccine. Amongst these groups, one group was given a placebo while the other three were given three separate vaccines. Talking about the results, Bharath Biotech stated:

The vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus.

COVAXIN and Covishield are among the top vaccine candidates to save us from the clutches of the deadly virus. 


WireX August Download

Muskan Bagrecha
Muskan is an undergraduate student pursuing a Bachelor's in Technology. With a zealous spirit for writing, she finds herself open to the vast realm of learning. She is an avid programmer with a keen interest in technology and science.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

What Elon Musk’s Starlink satellite internet means for India

Elon Musk’s SpaceX has revolutionized the space industry and now the California-based aerospace company works on delivering its promise of high-speed, low-latency internet to...

Inverter tech: How it functions and saves power

Inverter technology helps in saving energy by eliminating wasted operations in home appliances by efficiently controlling motor speed. This is often used in producing...

Windows 10 20H2 rollout marks end of these key features

Microsoft released the latest upgrade of Windows 10 — Windows 10 20H2 (with H2 standing for the second half) — this week. Although not every...

Adobe XD 34 update: New features and how are they useful

The Adobe XD 34 update is finally here. For those of you who don't know, Adobe XD is an all-in-one UX/UI solution to design...

Recent Comments